
R David Anderson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8851745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia. Journal of the American College of Cardiology, 2010, 55, 2825-2832.	2.8	660
2	Multisite Investigation of Outcomes WithÂlmplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	2.9	213
3	In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). American Heart lournal. 2011. 162. 678-684.	2.7	185
4	Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 646-653.	2.9	177
5	An Intravascular Ultrasound Analysis in Women Experiencing Chest Pain in the Absence of Obstructive Coronary Artery Disease: A Substudy from the National Heart, Lung and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Interventional Cardiology, 2010, 23, 511-519.	1.2	162
6	Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: Findings from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. American Heart Journal, 2013, 166, 134-141.	2.7	153
7	A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal, 2016, 37, 1504-1513.	2.2	152
8	Gender Differences in the Treatment for Acute Myocardial Infarction. Circulation, 2007, 115, 823-826.	1.6	132
9	Trends of Incidence, Clinical Presentation, and In-Hospital Mortality Among WomenÂWith Acute Myocardial InfarctionÂWith orÂWithout Spontaneous Coronary ArteryÂDissection. JACC: Cardiovascular Interventions, 2018, 11, 80-90.	2.9	92
10	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease. Circulation, 2017, 135, 1417-1428.	1.6	46
11	Incidence, Clinical Presentation, and Causes of 30-Day Readmission Following Hospitalization With Spontaneous Coronary Artery Dissection. JACC: Cardiovascular Interventions, 2020, 13, 921-932.	2.9	39
12	Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2018, 121, 32-40.	1.6	32
13	Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2017, 130, 1280-1289.	1.5	28
14	Prevalence, Causes, and Predictors of 30â€Day Readmissions Following Hospitalization With Acute Myocardial Infarction Complicated By Cardiogenic Shock: Findings From the 2013–2014 National Readmissions Database. Journal of the American Heart Association, 2018, 7, .	3.7	28
15	Acute Kidney Injury After Transcatheter Aortic Valve Replacement. Journal of Cardiac Surgery, 2016, 31, 416-422.	0.7	25
16	TIMI Frame Count and Adverse Events in Women with No Obstructive Coronary Disease: A Pilot Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2014, 9, e96630.	2.5	23
17	Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). Journal of Interventional Cardiology. 2019. 2019. 1-8.	1.2	22
18	Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). American Heart Journal, 2020, 220, 224-236.	2.7	15

R DAVID ANDERSON

#	Article	IF	CITATIONS
19	Percutaneous coronary intervention or coronary artery bypass grafting for unprotected left main coronary artery disease. Catheterization and Cardiovascular Interventions, 2017, 90, 541-552.	1.7	14
20	Safety and efficacy of secondâ€generation drugâ€eluting stents compared with bareâ€metal stents: An updated metaâ€analysis and regression of 9 randomized clinical trials. Clinical Cardiology, 2018, 41, 151-158.	1.8	14
21	Early and midterm outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valves. Journal of Cardiac Surgery, 2018, 33, 489-496.	0.7	13
22	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. International Journal of Cardiology, 2021, 326, 131-138.	1.7	13
23	Acetylcholine versus cold pressor testing for evaluation of coronary endothelial function. PLoS ONE, 2017, 12, e0172538.	2.5	13
24	Resting coronary velocity and myocardial performance in women with impaired coronary flow reserve: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. International Journal of Cardiology, 2020, 309, 19-22.	1.7	12
25	Early Invasive Strategy and Inâ€Hospital Survival Among Diabetics With Nonâ€STâ€Elevation Acute Coronary Syndromes: A Contemporary National Insight. Journal of the American Heart Association, 2017, 6, .	3.7	11
26	Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Research Protocols, 2017, 6, e255.	1.0	11
27	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
28	Coronary Vascular Function and Cardiomyocyte Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 3015-3021.	2.4	10
29	Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). International Journal of Cardiology, 2014, 172, e114-e115.	1.7	9
30	Pulse Pressure and Adverse Outcomes in Women: A Report From the Women's Ischemia Syndrome Evaluation (WISE). American Journal of Hypertension, 2008, 21, 1224-1230.	2.0	8
31	Statin Use in Men and New Onset of Erectile Dysfunction: A Systematic Review and Meta-Analysis. American Journal of Medicine, 2018, 131, 387-394.	1.5	7
32	Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine, 2019, 20, 612-618.	0.8	7
33	Impact of the ABCDâ€GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‧ite, Realâ€World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155.	4.7	7
34	The Coronary Microcirculation in STEMI: The Next Frontier?. European Heart Journal, 2015, 36, 3178-3181.	2.2	6
35	Staged versus index procedure complete revascularization in STâ€elevation myocardial infarction: A metaâ€analysis. Journal of Interventional Cardiology, 2017, 30, 397-404.	1.2	6
36	Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era. American Journal of Medicine, 2020, 133, 1254-1261.	1.5	5

#	Article	IF	CITATIONS
37	Percutaneous Inferior Vena Cava Valve Implantation May Improve Tricuspid Valve Regurgitation and Cardiac Output: Lessons Learned. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2020, 15, 577-580.	0.9	4
38	Are We There Yet?. JACC: Cardiovascular Interventions, 2015, 8, 1041-1043.	2.9	3
39	Maladaptive left ventricular remodeling in women: An analysis from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction study. International Journal of Cardiology, 2018, 268, 230-235.	1.7	3
40	Impact of Valve Size on Prosthesis–Patient Mismatch and Aortic Valve Gradient After Transcatheter versus Surgical Aortic Valve Replacement. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2019, 14, 243-250.	0.9	3
41	Outcomes of Direct Transcatheter Aortic Valve Replacement Without Balloon Aortic Valvuloplasty Using a New Generation Valve. Cardiovascular Revascularization Medicine, 2019, 20, 1100-1104.	0.8	2
42	Does RIDDLE-NSTEMI Provide an Answer to the Timing of ACS Therapy?. JACC: Cardiovascular Interventions, 2016, 9, 550-552.	2.9	1
43	Comparison of periprocedural and mid-term stroke rates and outcomes between surgical aortic valve replacement and transcatheter aortic valve replacement patients. Journal of Cardiovascular Surgery, 2017, 58, 591-597.	0.6	1
44	Does Ischemia Also Change as We Age?. JACC: Cardiovascular Interventions, 2020, 13, 30-32.	2.9	1
45	Transseptal mitral valve-in-valve replacement of intra-atrial mitral prosthesis in a patient with severe mitral annular calcification. JTCVS Techniques, 2021, 10, 266-268.	0.4	1
46	Transcatheter mitral valveâ€inâ€valve and valveâ€inâ€ring replacement: Lessons learned from bioprosthetic surgical valve failures. Journal of Cardiac Surgery, 2021, 36, 4024-4029.	0.7	1
47	Prognostic Value of Red Blood Cell Distribution Width in Transcatheter Aortic Valve Replacement Patients. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2021, 16, 155698452110413.	0.9	1
48	Multidisciplinary Management of a Hemophilia A Patient Requiring Coronary Artery Bypass Graft Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	1.3	1
49	Response to The J-Point Revisited. Hypertension, 2008, 51, .	2.7	Ο
50	Renal Denervation: Past, Present, and Future. Cardiovascular Innovations and Applications, 2016, 1, .	0.3	0
51	First generation bioresorbable vascular scaffolds: do they hold the promise?. Journal of Thoracic Disease, 2017, 9, 2293-2295.	1.4	Ο
52	Transcatheter Aortic Valve Replacement. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2018, 13, 120-124.	0.9	0
53	Current Status of Coronary Atherectomy. Cardiovascular Innovations and Applications, 2018, 3, .	0.3	0
54	ls it time to eliminate balloon valvuloplasty before transcatheter aortic valve replacement?. International Journal of Cardiology, 2019, 296, 53-54.	1.7	0

#	Article	IF	CITATIONS
55	Editorial: The use of Fascia iliaca Block with Minimal Conscious Sedation in Transcatheter Aortic Valve Replacement: Advances in TAVR Anesthesia. Cardiovascular Revascularization Medicine, 2020, 21, 602-603.	0.8	0
56	Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project. , 2021, 5, .		0
57	Myocardial Infarction and Persistent Angina With No Obstructive Coronary Artery Disease. JACC: Case Reports, 2020, 2, 9-14.	0.6	0
58	Paravalvular Leak: A Systemic Review. Current Cardiology Reviews, 2022, 18, .	1.5	0